XBiotech (XBIT) Research & Development (2014 - 2026)

XBiotech has reported Research & Development for 13 years, with the latest figure at $5.3 million in Q2 2026.

• On a quarterly basis, Research & Development fell 0.75% year-over-year to $5.3 million in Q2 2026; TTM through Jun 2026 was $41.1 million, a 28.73% increase from a year earlier, with the FY2025 full-year figure at $47.4 million, up 25.51% from the prior year.
• Research & Development was $5.3 million for Q2 2026 at XBiotech, down from $25.4 million in the prior quarter.
• The five-year high for Research & Development was $25.4 million in Q4 2025, with the low at $5.1 million in Q3 2025.
• Average Research & Development over 5 years is $9.1 million, with a median of $7.5 million recorded in 2023.
• The largest YoY upside for Research & Development was 224.23% in 2025 against a maximum downside of 58.9% in 2025.
• Over 5 years, Research & Development stood at $7.3 million in 2022, then climbed by 6.66% to $7.8 million in 2023, then increased by 0.22% to $7.8 million in 2024, then soared by 224.23% to $25.4 million in 2025, then slumped by 79.12% to $5.3 million in 2026.
• The last three Research & Development figures came in at $5.3 million (Q2 2026), $25.4 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.